OncoMatch/Clinical Trials/NCT07362914
Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions
Is NCT07362914 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Dexamethasone (12mg d1) and Dexamethasone (2mg QD, d1-5,) for breast cancer.
Treatment: Dexamethasone (12mg d1) · Dexamethasone (2mg QD, d1-5,) · Doxorubicin hydrochloride liposome · Cyclophosphamide — Investigating the Association Between Corticosteroid Use and Improvement in Doxorubicin Liposome-Induced Cutaneous Toxicity: Exploring the Feasibility and Mechanisms of Corticosteroids in Mitigating Liposomal Doxorubicin-Related Dermatologic Adverse Effects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: radiotherapy
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: biologics
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: targeted therapy
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: immunotherapy
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: antitumor treatments
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: liposomal doxorubicin or similar formulations
Previous treatment with liposomal doxorubicin or similar formulations.
Lab requirements
Blood counts
ANC ≥1.5 × 10⁹/L, Platelet count ≥75 × 10⁹/L, Hemoglobin ≥90 g/L
Kidney function
Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min
Liver function
Non-liver metastasis: TBIL ≤1.5 × ULN, ALT and AST ≤2.5 × ULN; Liver metastasis: TBIL ≤1.5 × ULN, ALT and AST ≤5 × ULN
Cardiac function
LVEF >50%, no severe arrhythmias/conduction abnormalities, no history of myocardial infarction, CABG, or heart failure (NYHA Class ≥II), QTcF ≤450 ms (males), ≤470 ms (females)
Hematologic: ANC ≥1.5 × 10⁹/L, Platelet count ≥75 × 10⁹/L, Hemoglobin ≥90 g/L; Hepatic: Non-liver metastasis: TBIL ≤1.5 × ULN, ALT and AST ≤2.5 × ULN; Liver metastasis: TBIL ≤1.5 × ULN, ALT and AST ≤5 × ULN; Renal: Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min; Coagulation: INR or PT ≤1.5 × ULN, APTT ≤1.5 × ULN; Cardiac: LVEF >50%, no severe arrhythmias/conduction abnormalities, no history of myocardial infarction, CABG, or heart failure (NYHA Class ≥II), QTcF ≤450 ms (males), ≤470 ms (females)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify